[HTML][HTML] A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open …
…, R Ochoa-Azze, Y Climent-Ruiz… - The Lancet Regional …, 2021 - thelancet.com
Background As a first step towards a vaccine protecting COVID-19 convalescents from
reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods Thirty COVID-19 …
reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods Thirty COVID-19 …
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
…, S Fernandez-Castillo, Y Climent-Ruiz… - Vaccine, 2022 - Elsevier
Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …
[HTML][HTML] Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor …
…, S Fernandez-Castillo, Y Climent-Ruiz… - International Journal of …, 2023 - Elsevier
Objectives To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o)
combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods A …
combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods A …
[HTML][HTML] Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with …
…, S Fernández-Castillo, Y Climent-Ruiz… - The Lancet Regional …, 2023 - thelancet.com
Background SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
[HTML][HTML] Caracterización de cepas de Neisseria meningitidis aisladas de portadores en Cuba durante 20 años
…, L Izquierdo Pérez, Y Climent Ruíz… - Revista Cubana de …, 2006 - scielo.sld.cu
Se investigaron los marcadores epidemiológicos de cepas de Neisseria meningitidis aisladas
de portadores en Cuba durante 20 años (1982-2002). Se identificaron los serogrupos, …
de portadores en Cuba durante 20 años (1982-2002). Se identificaron los serogrupos, …
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo …
…, A Chang-Monteagudo, Y Climent-Ruiz… - The Lancet …, 2022 - thelancet.com
Background A phase 1, clinical trial to evaluate FINLAY-FR-1A vaccine in COVID-19
convalescent individuals was completed. Here, we report results of the phase 2, clinical trial. …
convalescent individuals was completed. Here, we report results of the phase 2, clinical trial. …
[PDF][PDF] Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
…, S Fernandez-Castillo, Y Climent-Ruiz… - Med, 2022 - cell.com
Background SOBERANA 02 has been evaluated in phase I and IIa studies comparing
homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we …
homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we …
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity
…, R Ochoa-Azze, Y Climent-Ruiz… - Vaccine, 2022 - Elsevier
Background The Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is the
target for many COVID-19 vaccines. Here we report results for phase I clinical trial of two …
target for many COVID-19 vaccines. Here we report results for phase I clinical trial of two …
A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety …
A Chang-Monteagudo, R Ochoa-Azze, Y Climent-Ruiz… - medRxiv, 2021 - medrxiv.org
We evaluated response to a single dose of the FINLAY-FR-1A recombinant dimeric-RBD base
vaccine during a phase I clinical trial with 30 COVID-19 convalescents, to test its capacity …
vaccine during a phase I clinical trial with 30 COVID-19 convalescents, to test its capacity …
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA …
…, S Fernández-Castillo, Y Climent-Ruiz… - MedRxiv, 2022 - medrxiv.org
Background SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
